Anamar AB
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Subsidiary
- Established
- 1998-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.anamar.com
Safety, Tolerability and Pharmacokinetics of AM1476 in Healthy Subjects
- First Posted Date
- 2020-12-31
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- AnaMar AB
- Target Recruit Count
- 97
- Registration Number
- NCT04691115
- Locations
- 🇬🇧
Covance Clinical Research Unit, Leeds, United Kingdom
A Study to Assess the Safety, Tolerability, PK and PD of AM1030-CREAM in Patients With Atopic Dermatitis
Phase 1
Completed
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: AM1030-CREAM or placebo
- First Posted Date
- 2015-03-05
- Last Posted Date
- 2015-12-11
- Lead Sponsor
- AnaMar AB
- Target Recruit Count
- 36
- Registration Number
- NCT02379910
- Locations
- 🇬🇧
Covance CRU, Leeds, United Kingdom
🇬🇧CRLCRU Royal Liverpool University Hospital, Liverpool, United Kingdom
AMAP102 - Safety, Tolerability and Pharmacokinetics in Healthy Subjects
- First Posted Date
- 2009-10-15
- Last Posted Date
- 2009-10-15
- Lead Sponsor
- AnaMar AB
- Target Recruit Count
- 40
- Registration Number
- NCT00995605
- Locations
- 🇬🇧
Covance Clinical Research Unit Ltd., Leeds, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath